Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells
Cisplatin is a first-choice chemotherapeutic agent used to treat solid tumors even though the onset of multi-drug resistance and the time–dose side-effects impair its mono-therapeutic application. Therefore, new drug-delivery approaches, based on nanomedicine strategies, are needed to enhance its th...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-4991/11/6/1365 |
id |
doaj-aa2b342d27364241b6675aeea66b84b2 |
---|---|
record_format |
Article |
spelling |
doaj-aa2b342d27364241b6675aeea66b84b22021-06-01T00:45:07ZengMDPI AGNanomaterials2079-49912021-05-01111365136510.3390/nano11061365Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 CellsStefania Vernazza0Elena Dellacasa1Sara Tirendi2Laura Pastorino3Anna Maria Bassi4Department of Experimental Medicine, University of Genoa, 16132 Genoa, ItalyDepartment of Informatics, Bioengineering, Robotics and Systems Engineering, University of Genoa, 16145 Genoa, ItalyDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, ItalyDepartment of Informatics, Bioengineering, Robotics and Systems Engineering, University of Genoa, 16145 Genoa, ItalyDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, ItalyCisplatin is a first-choice chemotherapeutic agent used to treat solid tumors even though the onset of multi-drug resistance and the time–dose side-effects impair its mono-therapeutic application. Therefore, new drug-delivery approaches, based on nanomedicine strategies, are needed to enhance its therapeutic potential in favor of a dose-reduction of cisplatin. Polyunsaturated fatty acids and their metabolism-derived intermediates, as well as lipid peroxidation end-products, are used as adjuvants to improve the effectiveness of chemotherapy. Lipid hydroperoxides, derived from the oxidation of edible oils, can contribute to cell death, generating breakdown products (e.g., reactive aldehydes). In this regard, the aim of this present study was to evaluate an invitro combinatory strategy between a lecithin-based nanoemulsion system of K600, a patented mixture of peroxidated oil and peroxidated cholesterol, and cisplatin on DLD1 human adenocarcinoma cells. Our findings showed that nanoemulsions, acting in synergy with cisplatin, improve cisplatin bioactivity, in terms of enhancing its anti-cancer activity, towards DLD1 cells. Indeed, this combination approach, whilst maintaining cisplatin at low concentrations, induces a significant reduction in DLD1 cell viability, an increase in pro-apoptotic markers, and genotoxic damage. Therefore, K600 nanoemulsions as an efficient targeted delivery system of cisplatin allow for the reduction in the chemotherapeutic agent doses.https://www.mdpi.com/2079-4991/11/6/1365invitro studycancer cellsnanoemulsioncisplatinanticancer effects |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stefania Vernazza Elena Dellacasa Sara Tirendi Laura Pastorino Anna Maria Bassi |
spellingShingle |
Stefania Vernazza Elena Dellacasa Sara Tirendi Laura Pastorino Anna Maria Bassi Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells Nanomaterials invitro study cancer cells nanoemulsion cisplatin anticancer effects |
author_facet |
Stefania Vernazza Elena Dellacasa Sara Tirendi Laura Pastorino Anna Maria Bassi |
author_sort |
Stefania Vernazza |
title |
Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells |
title_short |
Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells |
title_full |
Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells |
title_fullStr |
Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells |
title_full_unstemmed |
Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells |
title_sort |
lipoperoxide nanoemulsion as adjuvant in cisplatin cancer therapy: in vitro study on human colon adenocarcinoma dld-1 cells |
publisher |
MDPI AG |
series |
Nanomaterials |
issn |
2079-4991 |
publishDate |
2021-05-01 |
description |
Cisplatin is a first-choice chemotherapeutic agent used to treat solid tumors even though the onset of multi-drug resistance and the time–dose side-effects impair its mono-therapeutic application. Therefore, new drug-delivery approaches, based on nanomedicine strategies, are needed to enhance its therapeutic potential in favor of a dose-reduction of cisplatin. Polyunsaturated fatty acids and their metabolism-derived intermediates, as well as lipid peroxidation end-products, are used as adjuvants to improve the effectiveness of chemotherapy. Lipid hydroperoxides, derived from the oxidation of edible oils, can contribute to cell death, generating breakdown products (e.g., reactive aldehydes). In this regard, the aim of this present study was to evaluate an invitro combinatory strategy between a lecithin-based nanoemulsion system of K600, a patented mixture of peroxidated oil and peroxidated cholesterol, and cisplatin on DLD1 human adenocarcinoma cells. Our findings showed that nanoemulsions, acting in synergy with cisplatin, improve cisplatin bioactivity, in terms of enhancing its anti-cancer activity, towards DLD1 cells. Indeed, this combination approach, whilst maintaining cisplatin at low concentrations, induces a significant reduction in DLD1 cell viability, an increase in pro-apoptotic markers, and genotoxic damage. Therefore, K600 nanoemulsions as an efficient targeted delivery system of cisplatin allow for the reduction in the chemotherapeutic agent doses. |
topic |
invitro study cancer cells nanoemulsion cisplatin anticancer effects |
url |
https://www.mdpi.com/2079-4991/11/6/1365 |
work_keys_str_mv |
AT stefaniavernazza lipoperoxidenanoemulsionasadjuvantincisplatincancertherapyinvitrostudyonhumancolonadenocarcinomadld1cells AT elenadellacasa lipoperoxidenanoemulsionasadjuvantincisplatincancertherapyinvitrostudyonhumancolonadenocarcinomadld1cells AT saratirendi lipoperoxidenanoemulsionasadjuvantincisplatincancertherapyinvitrostudyonhumancolonadenocarcinomadld1cells AT laurapastorino lipoperoxidenanoemulsionasadjuvantincisplatincancertherapyinvitrostudyonhumancolonadenocarcinomadld1cells AT annamariabassi lipoperoxidenanoemulsionasadjuvantincisplatincancertherapyinvitrostudyonhumancolonadenocarcinomadld1cells |
_version_ |
1721414017431371776 |